Related Experiment Video
Updated: Jul 6, 2026

Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products
Published on: December 5, 2020
Fungicidal versus Fungistatic: what's in a word?
James S Lewis1, John R Graybill
1University Health System, Department of Pharmacy, 4502 Medical Drive, San Antonio, TX 78229, USA. james.lewis@uhs-sa.com
Background:
Historically clinicians have preferred to use 'cidal' antifungal agents, particularly in critically ill patients. However, data to support the belief that the preferential use of a 'cidal' agent results in better patient outcomes has been lacking.
Objective:
This review examined the in vitro definitions of fungicidal and fungistatic as well as their strengths and limitations.
Methods:
A Medline search was performed in order to identify literature that examined the in vitro or in vivo impact of fungicidal and fungistatic activity. The study examined three common invasive fungal infections, namely cryptococcal meningitis, candidemia and invasive aspergillosis, where sufficient comparisons of fungicidal and fungistatic agents have been performed to allow for the evaluation of the clinical importance of these in vitro findings.
Results And Conclusion:
A clear clinical benefit of fungicidal agents over those with fungistatic activity remains elusive. Patients with cryptococcal meningitis clearly benefit from early fungicidal therapy but require long-term suppression. The data in invasive Candida sp. infections are tantalizing and suggest that fungicidal therapy may be important. However, the data for invasive aspergillosis do not support the hypothesis that fungicidal activity improves outcomes.
Insights
Clinicians often prefer fungicidal antifungal agents, but evidence for better outcomes is limited. This review found no clear clinical benefit of fungicidal over fungistatic agents, except for early cryptococcal meningitis treatment.
Area of Science:
- Mycology
- Infectious Diseases
- Clinical Pharmacology
Background:
- Clinicians historically favor fungicidal antifungal agents for critically ill patients.
- Evidence supporting improved patient outcomes with fungicidal agents is lacking.
- This review addresses the in vitro definitions and clinical relevance of fungicidal vs. fungistatic activity.
Purpose of the Study:
- To review the definitions of fungicidal and fungistatic antifungal activity.
- To evaluate the clinical significance of these in vitro properties.
- To assess the impact of fungicidal vs. fungistatic agents on patient outcomes in specific invasive fungal infections.
Main Methods:
- Systematic literature search of Medline for studies on fungicidal and fungistatic activity.
- Focused analysis on cryptococcal meningitis, candidemia, and invasive aspergillosis.
- Evaluation of studies comparing fungicidal and fungistatic agents in these infections.
Main Results:
- A definitive clinical advantage of fungicidal over fungistatic agents is not established.
- Early fungicidal therapy benefits cryptococcal meningitis patients, requiring subsequent suppression.
- Data for invasive Candida infections suggest potential benefits of fungicidal therapy.
- Evidence for invasive aspergillosis does not support improved outcomes with fungicidal activity.
Conclusions:
- The clinical benefit of fungicidal antifungal agents over fungistatic agents remains uncertain.
- Specific fungal infections show varied responses to fungicidal vs. fungistatic therapy.
- Further research is needed to clarify the role of fungicidal activity in invasive fungal infections.
Related Concept Videos
Antifungal Agents
Overview of Fungi
Methods for Controlling Microbial Growth
Chemical Agents for Microbial Control
Biodeterioration
Fungal Group Zygomycota

